New agents for the treatment of hepatitis C in patients co-infected with HIV

Therapeutic Advances in Infectious Disease

Volumn 1, Issue 2, 2013, Pages 71-80

  Munteanu, Daniela I ^a   Rockstroh, Jurgen K ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

DAA; hepatitis C; HIV; pegylated interferon; ribavirin

Indexed keywords

EID: 84993709368     PISSN: 20499361     EISSN: 2049937X     Source Type: Journal    
DOI: 10.1177/2049936113479591     Document Type: Review

References (27)

1. Bifano, M., Hwang, C., Oosterhuis, B., Hartstra, J., Tiessen, R. and Velinova-Donga, M. (2012) Assessment of HIV ARV drug interactions with the HCV NS5A replication complex inhibitor BMS-790052 demonstrates a pharmacokinetic profile which supports co-administration with tenofovir disoproxil fumarate, efavirenz, and atazanavir/ritonavir. CROI, Poster presentation 618.
2. Boesecke C. Mauss S. Rockstroh J. (2012) Management of HCV / HIV coinfection. In Mauss, Berg, Rockstroh, Sarrazin, Wedemeyer Hepatology 2012, third edition. Berlin: Flying Publisher.
3. Branch A. van Natta M. Vachon M. Dieterich D. Meinert C. Jabs D. for the Studies of the Ocular Complications of AIDS Research Group (2012) Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis. 55: 137–144.
4. de Kanter C. Blonk M. Colbers A. Schouwenberg B. Burger D. (2013) Lack of a clinically significant drug–drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis. 56: 300–306.
5. Fernandez-Montero J. Barreiro P. Vispo E. Labarga P. Rick F. Arredondo M. et al (2012) Baseline liver stiffness and achievement of sustained virological response predict liver complications and death in HIV / HCV coinfected patients receiving peginterferon / ribavirin therapy. Hepatology. 56(4 Suppl.): 650A–651A.
6. Fletcher, C. (2012) Clinical Pharmacology at the 13th Workshop on Clinical Pharmacology of HIV Therapy. http://www.natap.org/2012/pharm/Pharm_19.htm.
7. Hammond, H., Wolfe, P., Burton, J., Predhomme, J., Ellis, C., Ray, M., et al. (2012) Pharmacokinetic interaction between boceprevir and etravirine in HIV / HCV seronegative volunteers. Rev Antiviral Ther Infectious Dis 3: 17.
8. Hulskotte, E., Feng, H., Xuan, F., van Zutven, M., Treitel, M., Hughes, E., et al. (2012) Pharmacokinetic interactions between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir and darunavir. Clin Infect Dis 56: 718–726.
9. Ingiliz P. Rockstroh J. (2012) HIV–HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int. 32: 1194–1199.
10. Jacobson I. McHutchison J. Dusheiko G. Di Bisceglie A. Rajender Reddy K. Bzowej N. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 364: 2405–2416.
11. Kakuda T. Leopold L. Nijs S. Vandevoorde A. Crauwels H. Bertelsen K. et al. (2012) Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomised, two-way crossover trial. Rev Antiviral Ther Infectious Dis. 3: 20–21.
12. Kirby B. Mathias A. Rossi S. Moyer C. Shen G. Kearney B. (2012) No clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. Hepatology. 56(4 Suppl.): 1067A–1067A.
13. Lacombe K. Rockstroh J. (2012) HIV and viral hepatitis coinfections: advances and challenges. Gut. 61(Suppl. 1): i47–i58.
14. Lange C. Sarrazin C. (2012) Hepatitis C: new drugs. In Mauss, Berg, Rockstroh, Sarrazin, Wedemeyer Hepatology 2012, third edition. Berlin: Flying Publisher.
15. Merli M. Carbone A. Messina E. Galli L. Bagaglio S. Morsica G. et al (2012) Evolution of liver fibrosis in HIV/HCV-coinfected patients: impact of anti-HCV therapy in patients with different grades of liver stiffness. Hepatology. 56(4 Suppl.): 1031A–1031A.
16. Naggie S. Sulkowski M. (2012) Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 142: 1324–1334.
17. Ouwerkerk-Mahadevan, S., Sekar, V., Simion, A., Peeters, M. and Beumont-Mauviel, M. (2012 a) The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers. IDweek, poster 1618.
18. Ouwerkerk-Mahadevan, S., Sekar, V., Peeters, M. and Beumont-Mauviel, M. (2012 b) The pharmokinetic interactions of HCV protease inhibitor TMC 435 with RPV, TDF, EFV, or RAL in health volunteers. CROI, oral paper 49.
19. Poordad F. McCone J. Bacon B. Bruno S. Manns M. Sulkowski M. et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 364: 1195–206.
20. Piroth L. (2011) Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus. Clin Res Hepatol Gastroenterol. 35: S75–S83.
21. Rockstroh, J. (2012) HCV direct acting antivirals (DAAs) demonstrated to work in HIV / HCV coinfection: so how are treatment paradigms in HIV / HCV coinfection changing now? In Summary from CROI 2012 for Hepatitis Co-infection, http://www.natap.org/2012/CROI/croi_89.htm.
22. Schaefer M. Mauss S. (2012) Management of adverse drug reactions. In Mauss, Berg, Rockstroh, Sarrazin, Wedemeyer Hepatology 2012, third edition. Berlin: Flying Publisher.
23. Schwarze-Zander C. Rockstroh J.K. (2012) HIV protease inhibitors in combination with boceprevir: are drug-drug interactions the same for all patients? AIDS. 26: 1845–1846.
24. Soriano V. Vispo E. Poveda E. Labarga P. Martin-Carbonero L. Fernandez-Montero J. et al (2011) Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother. 66: 1673–1686.
25. Sulkowski M. (2013) HCV therapy in HIV-infected patients. Liver Int. 33(Suppl. S1): 63–67.
26. Sulkowski M. Sherman K. Soriano V. Rockstroh J. Dieterich D. Girard P. et al (2012) Telaprevir in combination with peginterferon alfa 2a / ribavirin in HCV / HIV co-infected patients: SVR 24 final study results. Hepatology. 56(4 Suppl.): 219A–219A.
27. Wilby K. Greanya E. Ford J. Yoshida E. Partovi N. (2012) A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplants patients. Ann Hepatol. 11: 179–185.